Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).
3don MSN
Why some lung transplant patients face higher rejection risk: Study points to key genetic variant
About one third of lung transplant recipients have a genetic variant that makes them more likely to develop chronic lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback